What evidence exists on Cosentyx (secukinumab) safety while breastfeeding?
Research directly focused on breastfeeding outcomes with secukinumab (Cosentyx) is limited. There is not robust clinical trial data showing breastfeeding safety in large groups of postpartum patients taking Cosentyx.
However, professional guidance and pharmacology-based reasoning generally consider whether the drug reaches breast milk in meaningful amounts and whether infants would be exposed after any ingestion. For monoclonal antibodies like secukinumab, the expected transfer into breast milk is often considered low, and the drug, if present, is likely to be broken down in the infant’s gastrointestinal tract rather than absorbed intact.
Are there any published case reports or observational data?
The available evidence base includes scattered reports and registry- or case-level documentation rather than large prospective breastfeeding studies. Those reports have not established a clear safety signal, but they also do not provide definitive proof because the number of documented breastfeeding exposures is relatively small.
If you want, tell me your country/region and whether you mean “while breastfeeding an infant” or “during pregnancy and then breastfeeding,” and I can narrow the answer to the most relevant guidance and any publicly documented cases.
What do guidelines typically recommend for breastfeeding on Cosentyx?
Most guidance for biologics like secukinumab takes a cautious but generally permissive stance when there is a medical need for maternal therapy, largely because of the expected low oral bioavailability to the infant (monoclonal antibodies are usually degraded in the gut). That said, recommendations often emphasize shared decision-making between the patient and prescriber, especially for newborns or premature infants.
What about newborns—are there extra precautions?
Even when breastfeeding is considered compatible, clinicians often pay extra attention to timing and infant age in practice. For example, some recommendations may be more cautious for preterm infants, very young newborns, or situations where the infant has medical risk factors, because any medication exposure is harder to weigh when baseline risk is higher.
What should patients discuss with their doctor before breastfeeding on Cosentyx?
Common discussion points include whether to:
- Continue Cosentyx during lactation based on the mother’s disease control needs.
- Monitor the infant for any signs of infection or poor feeding.
- Consider the infant’s age and health status (term vs preterm).
- Align on whether any alternative treatment would be more appropriate if there are concerns.
If you share the infant’s age (and whether term or preterm) and your country, I can summarize the most typical practical approach used by clinicians and the kind of monitoring usually suggested.